Antibiotic Pipeline Coordinators

Enrico Baraldi; Olof Lindahl; Miloje Savic; David Findlay; Christine Årdal

doi:10.1177/1073110518782912

Antibiotic Pipeline Coordinators

J Law Med Ethics. 2018 Jun;46(1_suppl):25-31. doi: 10.1177/1073110518782912.

Authors

Enrico Baraldi¹, Olof Lindahl¹, Miloje Savic¹, David Findlay¹, Christine Årdal¹

Affiliation

¹ Enrico Baraldi, Ph.D., is Professor of Industrial Engineering and Management at Uppsala University. His research focuses on innovation studies, business strategy, industrial marketing and purchasing, and commercialization of science. Olof Lindahl, Ph.D., is an Assistant Professor of International Business at Uppsala University. His research focuses on multinational corporations, managing innovation, and strategy. Miloje Savic, Ph.D., is a senior adviser on public health and antimicrobial resistance at the Norwegian Institute of Public Health. David Findlay, M.B.A., was a Global Commercial Director for anti-infectives at GSK and has a B.Sc. in Experimental Psychology from Reading University and an M.B.A. specializing in international business strategy from the University of Bradford's Management Centre. Christine Årdal, Ph.D., is a Senior Advisor at the Norwegian Institute of Public Health, co-lead for the DRIVE-AB research project, and co-lead on the European Union's Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections. Her research focuses are within antibiotic and neglected disease policy, particularly in regards to innovation and access.

PMID: 30146958
DOI: 10.1177/1073110518782912

Abstract

The World Health Organization (WHO) has published a global priority list of antibiotic-resistant bacteria to guide research and development (R&D) of new antibiotics. Every pathogen on this list requires R&D activity, but some are more attractive for private sector investments, as evidenced by the current antibacterial pipeline. A "pipeline coordinator" is a governmental/non-profit organization that closely tracks the antibacterial pipeline and actively supports R&D across all priority pathogens employing new financing tools.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents*
Drug Development / organization & administration*
Drug Discovery*
Drug Resistance, Microbial
Financing, Organized
Humans
Motivation
Research Support as Topic

Substances

Anti-Bacterial Agents